US Patent

US8999393 — Sustained release formulations of lorazepam

Method of Use · Assigned to EDGEMONT PHARMACEUTICALS LLC · Expires 2034-01-08 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition that delivers lorazepam in a prolonged fashion using sustained release beads.

USPTO Abstract

A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.

Drugs covered by this patent

Ativan (lorazepam) · Generic (originally Wyeth/Pfizer)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3210`	—	Ativan
`U-3210`	—	Ativan
`U-3210`	—	Ativan
`U-3210`	—	Ativan

Patent Metadata

Patent number: US8999393
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-08
Drug substance claim: No
Drug product claim: Yes
Assignee: EDGEMONT PHARMACEUTICALS LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.